Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. filed this Form 8-K on February 28, 2017, to report the entry into a Material Definitive Agreement. The Company is a biopharmaceutical firm focused on the clinical development of Resunab.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 3,887,815 shares.
- Offering Price: $7.00 per share.
- Gross Proceeds: Estimated at $27.2 million.
- Net Proceeds: Approximately $27.1 million after offering expenses.
- Use of Proceeds: Continued clinical development of Resunab, general corporate purposes, increasing working capital, and funding capital expenditures.
This filing does not provide historical revenue, profit, cash flow, margin, or debt figures for the Company.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of approximately 3.9 million new shares and the immediate increase in cash liquidity via the $27.1 million in net proceeds. No prior comparable period financial data is included in this specific filing to calculate percentage changes.
Guidance, Outlook, and Risks
Management intends to utilize the capital to advance the clinical development of Resunab. The filing contains forward-looking statements regarding the anticipated closing of the offering and the use of proceeds. Key risks include the Company's ability to satisfy closing conditions on a timely basis or at all, as well as other risks detailed in the Company's Form 10-K filed on March 28, 2016.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $27.1 million figure is an estimate.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and investor rights.
- Consult the Company's most recent Form 10-K (filed March 28, 2016) for historical financial performance and comprehensive risk factors.
- Confirm the updated share count and diluted ownership structure post-offering.